Neurology Specific Literature Search   
 
[home][thesaurus]
    

Differential
(Click to cross reference)
advances in neurology
adverse drug reaction
algorithm
andexanet
antiarrhythmic drugs
anticoagulant, complications of
anticoagulant, contraindications
anticoagulant, discontinuation
anticoagulant, restarting
anticoagulant, reversal of
anticoagulant, treatment
anticoagulant, treatment in CVD
anticoagulation effect
anticoagulation, perioperative
apixaban
argatroban
arrhythmia, cardiac
aspirin
asymptomatic
atrial appendage closure
atrial fibrillation
atrial fibrillation, nonvalvular
atrial fibrillation, risk stratification
atrial fibrillation, surgical treatment
atrial fibrillation, treatment
atrial flutter
atrial septal defect
bedridden
breast feeding
bridge therapy
bronchoscopy
cancer associated hypercoagulation
cancer, cerebrovascular accident complicating patients with
carcinoma
cardiomyopathy
carotid artery occlusion, intracranial
carotid artery occlusion, perioperative
CAT scan, abnormal
cataract surgery
cerebral embolism
cerebral embolism, cardiac origin
cerebral embolism, mechanical extraction
cerebral infarction
cerebral venous thrombosis
cerebrovascular accident
cerebrovascular accident, acute management of
cerebrovascular accident, cardiac disease causing
cerebrovascular accident, complications with
cerebrovascular accident, cryptogenic
cerebrovascular accident, postoperative
cerebrovascular accident, prevention of
cerebrovascular accident, primary prevention
cerebrovascular accident, recurrent
cerebrovascular accident, secondary prevention
cerebrovascular accident, severity
cerebrovascular accident, thrombolytic agents in treatment
cerebrovascular accident, women
cerebrovascular accident, young adult
CHADS-VaSC score
ciraparantag
clopidogrel
clot retrieval
colonoscopy
compliance
complications
controversies in neurology
cost
cost effectiveness
coumarin
coumarin, restarting treatment
coumarin, stopping treatment
cryoablation
dabigatran
dabigatran, dose
deafness, unilateral
delivery, complicated
dental procedure, neurologic complications with
dialysis
drug interactions
dural sinus thrombosis
dyspepsia
edoxaban
efficacy
electromyogram
embolic stroke of unknown source
embolism, systemic
endoscopic surgery
endoscopy
endovascular therapy
enoxaparin
evidence-based research
factor Xa inhibitor
falling
fibrinolytic agents
fibrinolytic agents, complications
fibrinolytic agents, contraindications
fibrinolytic agents, intra-arterial local infusion
fibrinolytic therapy, selection criteria
gastrointestinal bleeding
HAS-BLED score
head injury
headache
heart valve, prosthetic
hemorrhagic diathesis
hemostatic therapy
heparin
heparin, low-molecular-weight
heparinoid, low molecular weight
hepatic failure
hip arthroplasty
Holter monitoring
hormone replacement
hormone therapy
iatrogenic neurologic disorders
idarucizumab
incidental finding
INR value, time in range
INR values
intracerebral hemorrhage
intracerebral hemorrhage, progression of
intracerebral hemorrhage, silent
intracerebral hemorrhage, treatment of
intracerebral hemorrhage, volume
intracranial hemorrhage
labor, complicated
left atrial appendage, percutaneous closure
left ventricular dysfunction
liver disease
liver function enzymes
menopause
MERCI trial
microhemorrhage, intracerebral
middle cerebral artery, occlusion of
mimics
misdiagnosis
mortality
MRI, abnormal
myocardial infarction
neurologic complications of, surgery
neuroradiology, interventional
NIH stroke scale
non-vitamin K antagonist oral anticoagulants
non-vitamin K antagonist oral anticoagulants, coagulation test
number needed to treat
old age, neurology of
oral contraceptives
oral contraceptives, cerbrovascular disease and
ovarian induction
pacemaker, cardiac-transvenous
partial thromboplastin time
patent foramen ovale, surgical treatment of
patient information and support
peri-procedural
platelet inhibiting drugs
platelet inhibiting drugs, combined
platelet inhibiting drugs, discontinuation
postoperative neurologic complications
practice guidelines
pregnancy, neurologic complications in
prevention of neurologic disorders
prognosis
prothrombin complex concentrate
prothrombin time
prothrombin time, prolonged
radiofrequency ablation
rapid thromboelasticity
recanalization, arterial
recurrent
RELY trial
renal failure
reperfusion
RESPECT trial
review article
risk factors
risk factors, modification
risk stratification
risk-benefit assessment
rivaroxaban
ROCKET - AF trial
safety
serum alanine aminotransferase
solitaire device
SPORTIF trial
stent, carotid artery
subarachnoid hemorrhage
subarachnoid hemorrhage, cerebral convexity
subdural hematoma
T lesion of MCA-ICA
teratogenesis
teratogenic drugs
thrombectomy
thrombin inhibitor
thrombolysis, mechanical
thrombophlebitis
thrombus, mural
tissue plasminogen activator, intravenous
transient ischemic attack
transient neurologic deficit
transluminal angioplasty, coronary artery
transurethral prostatectomy
trauma
treatment of neurologic disorder
venous thrombosis, non-cerebral
vitamin K
vitamin K antagonist
Watchman device
ximelagatran
Showing articles 100 to 150 of 865 << Previous Next >>

Efficacy and Safety of Dabigatran Compared With Warfarin at Different Levels of International Normalised Ratio Control for Stroke Prevention in Atrial Fibrillation: An Analysis of the RE-LY Trial
Lancet 376:975-983, Wallentin,L.,et al, 2010

Dabigatran Versus Warfarin in Patients with Atrial Fibrillation
NEJM 361:1139-1151, 1200, Connolly,S.,et al, 2009

Combining Aspirin With Oral Anticoagulant Therapy: Is This a Safe and Effective Practice in Patients With Atrial Fibrillation?
Stroke 38:1652-1654, Gorelick,P.B., 2007

Direct Thrombin Inhibition and Stroke Prevention in Elderly Patients With Atrial Fibrillation: Experience From the SPORTIF III and V Trial
Stroke 38:2965-2971, Ford,G.A.,et al, 2007

Antithrombotic and Interventional Treatment Options in Cardioembolic Transient Ischaemic Attack and Ischaemic Stroke
JNNP 78:14-24, McCabe,D.J.H. &Rakhit,R.D., 2007

Secondary Stroke Prevention With Ximelagatran Versus Warfarin in Patients With Atrial Fibrillation: Pooled Analysis of SPORTIF III and V Clinical Trials
Stroke 38:874-880, Akins,P.T.,et al, 2007

Costs and Effectiveness of Ximelagatran for Stroke Prophylaxis in Chronic Atrial Fibrillation
JAMA 293:699-706, OBrien,C.L. &Gage,B.F., 2005

Ximelagatran--Promises and Concerns
JAMA 293:736-739, Gurewich,V., 2005

Ximelagatran vs Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation
JAMA 293:690-698,736, SPORTIF Executive Steering Committee for the SPORTIF V Investigators, 2005

Anticoagulants for Acute Ischemic Stroke
Stroke 35:2916-2917, Sandercock,P.,et al, 2004

Direct Thrombin Inhibition
Stroke 35:1519-1522, Elkind,M.S.V. &Sacco,R.L., 2004

Stroke Prevention with the Oral Direct Thrombin Inhibitor Ximelagatran Compared with Warfarin in Patients with Non-Valvular Atrial Fibrillation (SPORTIF III): Randomised Controlled Trial
Lancet 362:1691-1698,1686, Executive Steering Committee on Behalf of the SPOR, 2003

Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease
JAMA Neurol 92:19-29, Salloway,S.,et al, 2025

Inebilizumab for Treatment of IgG4-Related Disease
NEJM 392:1168-1177, Stone,J.H.,et al, 2025

Beyond Glucocorticoids for IgG4-Related Disease
NEJM 392:1232-1233, Spiera,R., 2025

Progress Toward Mitigating Disability Progression in Multiple Sclerosis
NEJM 392:1966-1968, Calabresi,P.A., 2025

Upadacitinib - An Up-and-Comer for Treatment of Giant-Cell Arteritis
NEJM 392:2062-2064, Koster,M.J. & Warrington,K.J., 2025

SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes
Neurol 103:e209805, Kim,H.K.,et al, 2024

Lecanemab for Alzheimer Disease, Is It Worth It?
Neurol 102:e209265, Nelson,S.E. & Lopez,O.L., 2024

Inhibition of CD40L with Frexalimab in Multiple Sclerosis
NEJM 390:589-600, 662, Vermersch,P.,et al, 2024

Diagnosis and Management of ANCA-Associated Vasculitis
Lancet 403:683-698, Kronbichler, A., et al, 2024

Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients with Atrial Cardiopathy, The ARCADIA Randomized Clinical Trial
JAMA 331:573-581, Kamel,H.,et al, 2024

Repurposing Erectile Dysfunction Medication for Alzheimer Disease Prevention
Neurol 102:e209180, Yasara,S., & Nidadavolu,L., 2024

Diagnosis and Management of Cerebral Venous Thrombosis:A Scientific Statement From the American Heart Association
Stroke 55:e77-e90, Saposnik,G.,et al, 2024

Chronic Immunotherapy for Myasthenia Gravis
www.UptoDate.Com, Bird,S.J., 2024

Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine, A Phase 4, Randomized, Placebo-Controlled Trial
JAMA Neurol 81:1140-1149, Tepper,S.J.,et al, 2024

Vitamin B12 Deficiency:NICE Guideline Summary
BMJ 385:q1019, q1262, Sands,T.,et al, 2024

Advances in Cerebral Venous Thrombosis
Stroke 55:2169-2172, deSousa,D.A. & Neto,L.L., 2024

Clinical Presentation, Management, and Outcome in Neurolymphomatosis, A Systematic Review
Neurol 103:e209698, Kaulen.L.D.,et al, 2024

Risk of Dementia After Initiation of Sodium-Glucose Cotransporter-2 Inhibitors Versus Dipeptidyl Peptidase-4 Inhibitors in Adults Aged 40-69 years with type 2 Diabetes:Population Based Cohort Study
BMJ doi:10.1136/BMJ-2024-07945, Shin,A., et al, 2024

Polymyalgia Rheumatica
Lancet 402:1459-1472, Espigol-Frigole,G.,et al, 2023

Severe Amyloid-Related Imaging Abnormalities After Anti-B-Amyloid Monoclonal Antibody Treatment
Neurol 101:1079-1080, Bonami,S.,et al, 2023

Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors in Patients with Melanoma
Neurol 101:e2472-e2482, Pepys,J.,et al, 2023

Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023

Progressive Hemiparesis and White Matter Abnormalities in an HIV-Negative Patient
Neurol 100:1156-1163, Jabbari,E.,et al, 2023

Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 330:512-517, 510, Sims,J.R.,et al, 2023

Clinicopathologic Conference, Encephalitis due to Behcets Disease
NEJM 387:925-933, Case 27-2022, 2022

In Patients with Melanoma Brain Metastases, is Combination Immune Checkpoint Inhibition a Safe and Effective First-Line Treatment? A Critically Appraised Topic
Neurologist 27:290-297, Gritsch, D.,et al, 2022

Lenvatinib Therapy for Advanced Thyroid Cancer: Real-Life Data on Safety, Efficacy, and Some Rare Side Effects
JENDSO 6:1-7, Hamidi, S.,et al, 2022

Atypical Posterior Reversible Encephalopathy Syndrome Associated with Lenvatinib Therapy in a Patient with Metastatic Thyroid-Cancer
Cancer Reports doi:10.1002/cnr2.1605, Abhishek, M.,et al, 2022

A 48-Year-Old Woman with 6 Months of Vivid Visual Hallucinations
Neurol 99:166-171, Kizza, J.,et al, 2022

Neuromyelitis Optica Spectrum Disorder
NEJM 387:631-639, Wingerchuk, D.M. & Lucchinetti, C.F., 2022

Progressive Vertebrobasilar Vasculopathy and Stroke Secondary to Giant Cell Arteritis
Stroke 53:e435-e438, Mahjoub, Y.,et al, 2022

Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory
Neurol 98:486-498, Turan, T.N.,et al, 2022

Idiopathic Intracranial Hypertension (Pseudotumor Cerebri): Prognosis and Treatment
www.UptoDate.com Mar, Wall, M. & Lee, A.G., 2022

Recent Advances in the Diagnosis and Management of Cluster Headache
BMJ 376:e059577, Schindler, E. & Burish, M.J., 2022

Confused About Confusion
NEJM 386:80-87, Spanjaart, A.M.,et al, 2022

Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary
Neurol 98:31-43, Price, R.,et al, 2022

Autoimmune Encephalitis Related to Cancer Treatment with Immune Checkpoint Inhibitors
Neurol 97:e191-e202, Nersesjan, V.,et al, 2021

The Effects of Long-Term Medication Use in Alzheimer Disease
Neurol 96:e2247-e2250, Karceski, S., 2021



Showing articles 100 to 150 of 865 << Previous Next >>